Resmed Inc
RMD- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000943819
In the last 90 days, Resmed Inc insiders filed 0 open-market purchases and 5 sales; 891 institutions reported holding it in 13F filings for Q2 2026, worth $19.4B in total; Giverny Capital is the only superinvestor holding it.
Other share classesRSMDF
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Resmed Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 5 filings
- 2 insiders, $5.26M in total
- Insiders trading
- 2
- Net value
- −$5.26M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Resmed Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Farrell Michael J. | Chairman and CEO | 466,256 | Sep 10, 2026 | 15 |
| Farrell Peter C | Director | 51,803 | Sep 4, 2026 | 11 |
| Rider Michael J | Global General Counsel | 9,488 | Jun 3, 2026 | 6 |
| Sandercock Brett | Chief Financial Officer | 83,495 | May 4, 2026 | 9 |
| De Witte Jan | Director | 4,261 | Nov 26, 2025 | 3 |
| Mowad-Nassar Nicole | Director | 777 | Nov 26, 2025 | 2 |
| Taylor Ronald R | Director | 24,771 | Nov 24, 2025 | 1 |
| Burt Carol | Director | 2,156 | Nov 24, 2025 | 1 |
| Drexler Karen | Director | 10,602 | Nov 24, 2025 | 1 |
| Gill Harjit | Director | 10,940 | Nov 24, 2025 | 2 |
| Leong Justin | Chief Product Officer | 29,028 | Nov 24, 2025 | 1 |
| DelOrefice Christopher | Director | 2,423 | Nov 24, 2025 | 1 |
| Tan Desney | Director | 6,002 | Nov 24, 2025 | 1 |
| Hernandez John | Director | 5,118 | Nov 24, 2025 | 1 |
| Sulpizio Richard | Director | 17,796 | Nov 21, 2025 | 1 |
| Ghoshal Kaushik | Chief Commercial Officer, SaaS | 9,725 | Aug 5, 2025 | 0 |
| Douglas Robert Andrew | Special Advisor | 13,849 | Jan 3, 2024 | 0 |
| Blaise Lucile | President, Sleep & RC Business | 10,305 | Nov 16, 2023 | 0 |
| Pendarvis David | Chief Administrative Officer | 89,729 | Jun 30, 2023 | 0 |
| Hollingshead James | President, Sleep Business | 76,721 | Dec 1, 2021 | 0 |
| Resmed Inc | Director | 13,823 | Nov 22, 2021 | 0 |
| Sodhi Rajwant | President, SaaS Business | 26,731 | Oct 14, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2022 (view filing) | Nov 7 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −4.00K | $212.02 | −$848.1K | −3.6%106.3K after | |
| Nov 4, 2022 (view filing) | Nov 3 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $215.23 | −$332.5K | −1.5%102.3K after | |
| Nov 2, 2022 (view filing) | Oct 31 | 2 days | Farrell Peter CDirector | SSaleResMed Common Stock | −9.05K | $221.98 | −$2.01M | −4.7%183.1K after | |
| Oct 18, 2022 (view filing) | Oct 17 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $214.58 | −$1.22M | −1.3%422.6K after | |
| Oct 17, 2022 (view filing) | Oct 14 | 3 days | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −11.4K | $215.09 | −$2.44M | −24.5%35.1K after | |
| Oct 5, 2022 (view filing) | Oct 3 | 2 days | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $220.19 | −$340.2K | −1.5%103.9K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $228.96 | −$1.30M | −1.3%422.6K after | |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −11.2K | $232.51 | −$2.60M | −28.3%28.4K after | |
| Sep 16, 2022 (view filing) | Sep 15 | 1 day | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −6.00K | $232.38 | −$1.39M | −2.6%229.0K after | |
| Sep 7, 2022 (view filing) | Sep 6 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $216.92 | −$335.1K | −1.4%105.4K after | |
| Aug 17, 2022 (view filing) | Aug 15 | 2 days | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $238.09 | −$1.35M | −1.4%405.3K after | |
| Aug 12, 2022 (view filing) | Aug 10 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $240.66 | −$601.6K | −2.3%106.4K after | |
| Aug 4, 2022 (view filing) | Aug 3 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $240.72 | −$371.9K | −1.4%105.3K after | |
| Jul 26, 2022 (view filing) | Jul 22 | 4 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −7.50K | $235.00 | −$1.76M | −6.6%106.4K after | |
| Jul 18, 2022 (view filing) | Jul 15 | 3 days | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $224.94 | −$1.28M | −1.4%405.3K after | |
| Jul 6, 2022 (view filing) | Jul 5 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $212.33 | −$328.0K | −1.4%106.8K after | |
| Jun 16, 2022 (view filing) | Jun 15 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $202.54 | −$1.15M | −1.4%405.3K after | |
| Jun 7, 2022 (view filing) | Jun 3 | 4 days | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $209.44 | −$323.6K | −1.4%108.4K after | |
| May 17, 2022 (view filing) | May 16 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $196.61 | −$1.12M | −1.4%405.3K after | |
| May 4, 2022 (view filing) | May 3 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $200.00 | −$309.0K | −1.4%109.9K after | |
| Apr 19, 2022 (view filing) | Apr 18 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $232.41 | −$1.32M | −1.4%405.2K after | |
| Apr 19, 2022 (view filing) | Apr 18 | 1 day | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −8.00K | $233.29 | −$1.87M | −31.8%17.2K after | |
| Apr 12, 2022 (view filing) | Apr 11 | 1 day | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $247.00 | −$617.5K | −2.3%106.4K after | |
| Apr 5, 2022 (view filing) | Apr 4 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $246.60 | −$380.8K | −1.4%111.4K after | |
| Mar 16, 2022 (view filing) | Mar 15 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $242.37 | −$1.38M | −1.4%405.2K after | |
| Mar 16, 2022 (view filing) | Mar 15 | 1 day | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −8.00K | $238.07 | −$1.90M | −31.8%17.2K after | |
| Mar 14, 2022 (view filing) | Mar 10 | 4 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $241.29 | −$603.2K | −2.3%106.4K after | |
| Mar 4, 2022 (view filing) | Mar 3 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $250.62 | −$387.0K | −1.3%112.9K after | |
| Feb 16, 2022 (view filing) | Feb 15 | 1 day | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $234.06 | −$1.33M | −1.4%405.2K after | |
| Feb 16, 2022 (view filing) | Feb 15 | 1 day | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −8.00K | $235.81 | −$1.89M | −31.8%17.2K after | |
| Feb 14, 2022 (view filing) | Feb 10 | 4 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $241.86 | −$604.6K | −2.3%106.4K after | |
| Feb 4, 2022 (view filing) | Feb 3 | 1 day | Pendarvis DavidChief Administration Officer | SSaleResMed Common Stock | −1.54K | $232.87 | −$359.6K | −1.3%114.5K after | |
| Jan 20, 2022 (view filing) | Jan 18 | 2 days | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −8.00K | $247.80 | −$1.98M | −31.8%17.2K after | |
| Jan 20, 2022 (view filing) | Jan 18 | 2 days | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $241.94 | −$1.37M | −1.4%405.2K after | |
| Jan 11, 2022 (view filing) | Jan 10 | 1 day | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $235.00 | −$587.5K | −2.3%106.4K after | |
| Jan 4, 2022 (view filing) | Jan 3 | 1 day | Pendarvis DavidChief Administration Officer | SSaleResMed Common Stock | −1.54K | $258.52 | −$399.2K | −1.3%116.0K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Douglas Robert AndrewPresident and COO | SSaleResMed Common Stock | −8.00K | $256.52 | −$2.05M | −31.8%17.2K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Farrell Michael J.Chief Executive Officer | SSaleResMed Common Stock | −5.67K | $255.53 | −$1.45M | −1.4%405.2K after | |
| Dec 14, 2021 (view filing) | Dec 10 | 4 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $264.92 | −$662.3K | −2.3%106.4K after | |
| Dec 6, 2021 (view filing) | Dec 3 | 3 days | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.54K | $257.93 | −$398.2K | −1.3%117.6K after | |
| Dec 1, 2021 (view filing) | Dec 1 | Same day | Hollingshead JamesPresident, Sleep Business | SSaleResMed Common Stock | −2.40K | $256.84 | −$616.4K | −3.0%76.7K after | |
| Nov 23, 2021 (view filing) | Nov 22 | 1 day | Burt CarolDirector | SSaleResMed Common Stock | −1.50K | $260.00 | −$390.0K | −10.3%13.1K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Burt CarolDirector | SSaleResMed Common Stock | −1.19K | $270.80 | −$321.4K | −100.0%0 after | |
| Nov 15, 2021 (view filing) | Nov 15 | Same day | Douglas Robert AndrewPresident and COO ResMed Inc. | SSaleResMed Common Stock | −8.00K | $271.75 | −$2.17M | −27.3%21.3K after | |
| Nov 12, 2021 (view filing) | Nov 10 | 2 days | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −2.50K | $260.58 | −$651.5K | −2.9%84.8K after | |
| Nov 5, 2021 (view filing) | Nov 3 | 2 days | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.49K | $264.29 | −$392.5K | −1.2%121.0K after | |
| Nov 1, 2021 (view filing) | Nov 1 | Same day | Hollingshead JamesPresident, Sleep Business | SSaleResMed Common Stock | −2.40K | $264.35 | −$634.4K | −3.2%73.2K after | |
| Oct 18, 2021 (view filing) | Oct 15 | 3 days | Douglas Robert AndrewPresident and COO ResMed Inc. | SSaleResMed Common Stock | −8.00K | $255.77 | −$2.05M | −26.5%22.1K after | |
| Oct 12, 2021 (view filing) | Oct 11 | 1 day | Sandercock BrettChief Financial Officer | SSaleResMed Common Stock | −5.00K | $253.37 | −$1.27M | −5.6%84.8K after | |
| Oct 5, 2021 (view filing) | Oct 4 | 1 day | Pendarvis DavidChief Administrative Officer | SSaleResMed Common Stock | −1.49K | $260.79 | −$387.8K | −1.2%122.5K after |